Monopar Therapeutics

Monopar Therapeutics (MNPR) has registered zero cyber incidents and zero red-flag 8-K filings in our 90-day monitoring window, indicating stable near-term operations. However, low signal in a short window does not eliminate structural risks; the company operates in the capital-intensive biotech sector where financing history, dilution patterns, and runway metrics drive valuation. The full $49 Report pulls 12 months of filing data, calculates dilution risk scores, contextualizes all 8-K activity, and surfaces AI-detected financing and solvency signals that shape investment thesis. The full $49 Report adds comprehensive dilution analysis, 12-month 8-K context, financing trajectory, and machine-detected structural risks.